Dendritic Cell Immunotherapy is a type of treatment that uses the body’s own immune cells, called dendritic cells, to help fight cancer. In this trial, the therapy is designed to target a specific protein known as WT1, which is found in certain types of brain tumors in children. The goal is to help the immune system recognize and attack the cancer cells more effectively. This therapy is used alongside other standard treatments or after previous therapies to see if it can improve outcomes for patients with high-grade glioma and diffuse intrinsic pontine glioma.

Diffuse Intrinsic Pontine Glioma (DIPG) – This is a rare and aggressive brain tumor that occurs in the pons, a part of the brainstem. It primarily affects children and is characterized by rapid growth, leading to a range of neurological symptoms. As the tumor progresses, it can cause difficulties with balance, movement, and coordination, as well as problems with vision and swallowing. The tumor’s location in the brainstem makes it difficult to treat surgically. DIPG often leads to increased pressure within the skull, contributing to headaches and other symptoms. The progression of the disease can vary, but it typically advances quickly.

High-Grade Glioma (HGG) – This is a type of fast-growing brain tumor that can occur in various parts of the brain. It is known for its aggressive nature and tendency to infiltrate surrounding brain tissue. As the tumor grows, it can cause symptoms such as headaches, seizures, and changes in personality or cognitive function. The tumor’s rapid growth can lead to increased pressure in the brain, resulting in additional neurological symptoms. HGGs are often challenging to treat due to their location and aggressive behavior. The progression of the disease can be swift, affecting the patient’s quality of life.